Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MPO | P05164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32680072 | 1.00 | CYP1A2 (0.61) | CYP1A2KDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL13332558 | 0.86 | CYP1A2 (0.62) | CYP1A2KDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL3311829 | 0.85 | CYP1A2 (0.57) | CYP1A2KDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL31160820 | 0.84 | KMT2A (0.53) | KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL11985495 | 0.84 | CYP1A2 (0.67) | CYP1A2KDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL7231747 | 0.82 | KDM4E (0.67) | CYP1A2KDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL10084475 | 0.82 | HSD17B10 (0.47) | KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL3311524 | 0.82 | ALDH1A1 (0.73) | CYP1A2KDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL2696822 | 0.81 | KDM4E (0.45) | KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL8922778 | 0.81 | PARG (0.45) | CYP1A2KDM4EHPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564547-B2 | Compositions, formulations, and methods for skin treatment | ODDITY LABS, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| WO-2023133240-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | REVELA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20200369626-A1 | COMPOSITIONS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR 2 (S1PR2) BINDING AGENTS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8633211-B2 | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-2132186-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | Novartis AG (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107436-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| US-6407116-B1 | 2,4-DIOXO-1,2,3,4-TETRAHYDROQUINAZOLINE DERIVATIVES; ANTIALLERGENS, ANTIASTHMATICS, ANTIHISTAMINES, AND ANTIINFLAMMATORY AGENTS | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1026160-A1 | NITROGENOUS FUSED-RING COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME, AND DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | CUTA, COL14A1, DSG1 | CYP1A2 2664/4885KDM4E 1659/4885HPGD 1792/4885 |
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | S1PR3, S1PR1, S1PR2 | CYP1A2 539/4885KDM4E 3052/4885HPGD 2063/4885 |
| US-12564547-B2 | Compositions, formulations, and methods for skin treatment | MCOLN1, H1-0, APOL1 | CYP1A2 895/4885KDM4E 2683/4885HPGD 4173/4885 |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | S1PR3, S1PR1, S1PR2 | CYP1A2 576/4885KDM4E 2815/4885HPGD 2160/4885 |
| US-20200369626-A1 | COMPOSITIONS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR 2 (S1PR2) BINDING AGENTS AND USES THEREOF | S1PR2, S1PR1, S1PR3 | CYP1A2 4307/4885KDM4E 4281/4885HPGD 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.